Streetbeat News

NVEI

Nuvei Corporation

https://www.nuvei.com

Industry

Software - Infrastructure

Nuvei Corporation provides payment technology solutions to merchants and partners in North America, Europe, the Middle East and Africa, Latin America, and the Asia Pacific. It provides a suite of payment solutions to support lifecycle of a transaction across mobile or in-app, online, unattended, and in-store channels. The company sells and distributes its solutions through direct sales, indirect sales for small-and-medium sized businesses, and eCommerce resellers. Nuvei Corporation was founded in 2003 and is headquartered in Montreal, Canada.

Open

33.98

Mkt cap

4.8B

Volume

3.1M

High

34.00

P/E Ratio

212.44

52-wk high

34.00

Low

33.98

Div yield

0.01

52-wk low

19.07

On Wednesday, 155 companies set new 52-week lows. The largest company by market cap to set a new 52-week low was Estee Lauder Cos (NYSE:EL). The smallest company by market cap to set a new 52-week low was SenesTech (NASDAQ:SNES). Siyata Mobile (NASDAQ:SYTA)'s stock fell the most, as it traded down 7658.62% to reach a new 52-week low. Sutro Biopharma (NASDAQ:STRO) was the biggest winner of the bunch, with shares actually trading up 0.0% after it rebounded from its new 52-week low.

Portfolio Pulse from Benzinga Insights

August 09, 2023 | 4:27 pm

US stocks were lower with the Nasdaq Composite falling around 1%. Energy shares jumped by 1.1% while information technology shares fell 1.3%. Tango Therapeutics, Decibel Therapeutics, and Renovaro Biosciences saw their shares rise significantly. Palisade Bio, Tigo Energy, and Nuvei Corporation shares dropped. U.S. crude oil inventories increased by 5.851 million barrels, exceeding market expectations.

Portfolio Pulse from Lisa Levin

August 09, 2023 | 4:25 pm

US stocks were mostly lower with the Nasdaq Composite falling more than 50 points. Charles River Laboratories International, Inc. (CRL) reported better-than-expected Q2 results and raised its FY23 non-GAAP EPS estimate. Tango Therapeutics (TNGX), Decibel Therapeutics (DBTX), and Renovaro Biosciences (RENB) saw their shares rise significantly. Palisade Bio (PALI), Tigo Energy (TYGO), and Nuvei Corporation (NVEI) shares fell due to disappointing results and guidance.

Portfolio Pulse from Lisa Levin

August 09, 2023 | 2:09 pm

Nuvei reported mixed Q2 financial results and issued Q3 revenue guidance below estimates, causing its shares to trade lower.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2023 | 12:48 pm

Nuvei Corp has announced a quarterly cash dividend of $0.10 per share, payable on September 5, 2023 to shareholders of record as of August 21, 2023. The total dividend payout is expected to be around $15 million, funded from the company's existing cash reserves.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2023 | 11:20 am

Nuvei Corp has revised its Q3 revenue forecast to $300M-$308M, lower than the estimated $316.85M. However, the company has increased its FY23 revenue projection to $1.225B-$1.264B from the previous $1.170B-$1.195B, which is still slightly below the estimated $1.24B.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2023 | 11:12 am

Nuvei reported Q2 earnings of $0.39 per share, missing the analyst consensus estimate of $0.44 by 11.36%. This is a 23.53% decrease from the same period last year. However, the company's quarterly sales of $307.03 million beat the analyst consensus estimate of $305.77 million by 0.41%, marking a 45.31% increase from last year.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2023 | 11:02 am

Nuvei and Plaid have announced plans to extend their partnership to new regions and eCommerce verticals. They also intend to scale their partnership globally before the end of the year.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2023 | 11:05 am

Analysts have provided bullish and somewhat bullish ratings for Nuvei (NASDAQ:NVEI) in the last quarter. In the last 3 months, 7 analysts have offered 12-month price targets for Nuvei, with an average price target of $48.43. The average price target has increased by 0.48% over the past month.

Portfolio Pulse from Benzinga Insights

July 13, 2023 | 4:01 pm

Goldman Sachs analyst Will Nance has maintained a 'Buy' rating on Nuvei (NASDAQ:NVEI), but lowered the price target from $48 to $41.

Portfolio Pulse from Benzinga Newsdesk

July 13, 2023 | 11:20 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.